Changchun Bcht Biotechnology (688276.SH): Net profit for 2024 is 239 million yuan, a decrease of 52.31% year-on-year.

Changchun Bcht Biotechnology (688276.SH) released its 2024 annual performance report, with the company achieving operating income of 1.229 billion yuan, a year-on-year decrease of 32.64%; net profit attributable to shareholders of the listed company was 239 million yuan, a year-on-year decrease of 52.31%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 237 million yuan, a year-on-year decrease of 52.06%; basic earnings per share were 0.58 yuan per share. The main factors affecting the performance change in 2024 were the decrease in public willingness to receive vaccines and the reduction in market demand. The sales and use of the company's live attenuated herpes zoster vaccine were greatly affected, leading to a decrease in the number of vaccinations and shipments, and a decline in both total operating income and net profit year-on-year. To address these challenges, the company will continue to optimize its marketing system, increase investment in public education and promotion, enhance public awareness of relevant diseases through official and new media, stimulate user demand. At the same time, optimize the digital marketing model, achieve online and offline coverage, increase market share of products, and enhance the company's core competitiveness and industry recognition.